- Bone Marrow Transplant Research
- Botox Research And News
- Complementary Therapies
- Cognition and Cognitive Issues Research
- Diet
- Drugs
- » Aimspro (Goats Serum)
- » Ampyra (Fampyra)
- » ATX-MS-1467
- » Azathioprine
- » BG-12
- » BHT-3009
- » Cannabis And Cannabinoid Research
- » CHR-1103
- » Cladribine
- » Cyclophosphamide
- » Cyrevia
- » Disease Modifying Drugs
- » Genetically Modified Drugs And Components
- » Gilenya® (fingolimod)
- » Laquinimod
- » Lemtrada (alemtuzumab)
- » Low Dose Naltrexone - Latest News
- » Masitinib
- » MBP8298
- » Minocycline
- » Mitoxantrone and Copaxone Combination Therapy
- » MN-166 (Ibudilast)
- » Modafinil
- » NeuroVax
- » Novantrone (Mitoxantrone)
- » PEGylated interferon beta
- » Prokarin
- » Pycnogenol
- » Rituximab (Rituxan)
- » RPI-78M
- » RTL-1000
- » Sativex®
- » Statins
- » Tcelna(TM)
- » Teriflunomide (Aubagio™)
- » Trimesta (Oral Estriol)
- » Viagra (sildenafil)
- » Zenapax (daclizumab)
- » Further Possible MS Drugs and Treatments
- » Possible Drugs For The Treatment Of MS Symptoms
- Endo-parasites & 'Helpful' Organisms
- Environmental Factors And MS Research
- Ethnic Groups and MS Research
- Exercise
- Familial Risk of Multiple Sclerosis Research
- General Health
- General Research Articles
- General Research News
- Hyperbaric Oxygen Therapy Research
- Lightning Process® And Multiple Sclerosis Research
- Mercury Amalgam Fillings Research
- MS and Genetics Research
- MS Knowledge
- Myelin Research
- Neuropsychiatric and Psychological Research
- New Discoveries
- Optical Assessments and MS Research
- Other Conditions Research
- Paediatric Multiple Sclerosis Research
- Pain Research
- Pregnancy And MS Research
- Quality Of Life Research
- Sex
- Stem Cell Research & Treatment
- Vaccinations & MS Research
- Vitamin B12 Research
- Vitamin D Research & News
Modafinil
|
|
| MS Fatigue Drug Therapy | |
| For the first time, researchers here have found an effective therapy that can alleviate the fatigue often accompanying multiple sclerosis. Fatigue is one of the most common and disabling symptoms of multiple sclerosis. It affects 75 to 90 percent of patients with the disease. Two doses of modafinil (200 and 400 mg) were compared against a placebo in 72 patients with multiple sclerosis ranging in age from 18 to 65. It was observed that the 200 mg dose of the drug administered once daily showed highly significant improvement in patients. "We were very pleased to find that a medication that was effective” said Rammohan, lead author of the study. Rammohan's group also looked at the potential side effects associated with this medication and found that they were not greater than those experienced by patients in the study who received a placebo. No previous drug has been able to show this degree of improvement in treating multiple sclerosis-related fatigue in any previous clinical trial. Source: Columbus, Ohio © Multiple Sclerosis Resource Centre
|
| Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us. |